ImmuPharma PLC (AIM:IMM) announced that Professor Sylviane Muller, inventor of specialist drug company’s lead asset Lupuzor and P140 technology has been awarded the ‘Légion d'honneur', France’s highest decoration.
Lupuzor is being developed for the treatment of the autoimmune disease Lupus and ImmuPharma together with partner Avion Pharma is readying to take the drug into a phase III trial.
Yesterday, ImmuPharma announced that “active preparation” was being made for a phase II/III clinical study to evaluate P140 in a new area of interest - chronic inflammatory demyelinating polyneuropathy (CIDP), a neurological disorder targeting the body's nerves.
Commenting on the award, ImmuPharma chief executive and chairman Tim McCarthy said: "On behalf of the board and the whole team at ImmuPharma, we congratulate Prof. Muller on this highly prestigious award, which is highly deserving, in recognition of her many years of work and commitment to understanding the complexities of the human immune system.
“We are hugely honoured to be working in partnership with Prof. Muller on Lupuzor and the P140 platform, in which her passion and drive and collaborative approach has been an invaluable contribution to our clinical team, as we move closer to offering therapeutic drugs, initially in lupus, which will be of enormous benefit to patients."
Shares were 2.43% higher at 7.58p in early morning trade.